GEN Exclusives

More »

GEN Poll

More »
Mar 14, 2012

Declining Euro

One indication of the impact the falling Euro has had on biopharma is the rising unpaid debt owed by European governments to the industry, which climbed more than 50% just from November to February. Several biopharma giants also saw sales slumps and attribute it to the Euro or trends stemming from the Euro’s slide. GlaxoSmithKline, for example, blamed European pricing pressure for a 5% (£320 million or about $500 million) decline in regional sales during 2011; it expects a similar impact in 2012. The Euro slide has caused Germany to tighten its rules governing pricing of new drugs. The result of the Euro’s woes on biopharma can be seen most in the currency’s home continent. Will it extend to the U.S.?

How much effect do you think the Euro crisis will have on the U.S. biopharma industry?

A Lot
Not Much


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »